Summit Therapeutics And Lunit Announce A Research Agreement To Evaluate The Use Of Lunit SCOPE IO For Tumor Microenvironment Analysis In Support Of Summit’s Immuno-Oncology Development Programs With Ivonescimab

Loading news article.

Summit Therapeutics And Lunit Announce A Research Agreement To Evaluate The Use Of Lunit SCOPE IO For Tumor Microenvironment Analysis In Support Of Summit’s Immuno-Oncology Development Programs With Ivonescimab | WAPE

Summit Therapeutics And Lunit Announce A Research Agreement To Evaluate The Use Of Lunit SCOPE IO For Tumor Microenvironment Analysis In Support Of Summit’s Immuno-Oncology Development Programs With Ivonescimab

Article summary

Related companies

Comments —